Phenobarbital

證據等級: L5

預測適應症: 10 個

Phenobarbital: From Epilepsy to Trigeminal Nerve Neoplasm

One-Sentence Summary

Phenobarbital is a classic barbiturate, established for the long-term treatment of epilepsy and seizure disorders. The TxGNN model’s top-ranked new indication is Trigeminal Nerve Neoplasm, but this prediction is currently supported by only 1 unrelated case series and 0 clinical trials — evidence is not yet meaningful.

Quick Overview

Item	Content
Original Indication	Epilepsy / Seizure disorders (based on established pharmacological classification; no formal label text available — this evidence pack contains no `original_indications` or license data for this drug)
Predicted New Indication	Trigeminal Nerve Neoplasm
TxGNN Prediction Score	99.96%
Evidence Level	L5
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (original_moa = Data Gap). Based on information embedded elsewhere in this evidence pack, phenobarbital is understood to be a GABA-A receptor positive allosteric modulator with central nervous system depressant and anticonvulsant activity — the pharmacological basis for its established use in epilepsy.

For this specific top-ranked prediction, however, the evidence pack’s own rationale explicitly flags the pairing as likely knowledge-graph noise: there is no known biological link between phenobarbital’s GABA-A-mediated CNS-suppressant/anticonvulsant mechanism and tumour growth suppression relevant to a trigeminal nerve neoplasm. The single supporting publication is a 1997 case series on Sturge-Weber syndrome (a vascular/seizure disorder), which does not address nerve tumour treatment and is only tangentially connected through shared neurological terminology.

It is worth noting that several lower-ranked candidates in this evidence pack (e.g., audiogenic seizures, rank 6) have substantially stronger and more mechanistically coherent support — multiple preclinical studies directly testing phenobarbital in reflex-seizure animal models — and may warrant separate evaluation as they represent extensions of phenobarbital’s existing antiepileptic mechanism rather than an unrelated oncology application.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9157801	1997	Case Series	Anales españoles de pediatría	Reviews 14 cases of Sturge-Weber syndrome over a 25-year period; does not address trigeminal nerve neoplasm treatment or phenobarbital efficacy against tumour growth

US Market Information

Phenobarbital is not currently marketed in the US per this evidence pack (market_status: 未上市 / Not Marketed), and no NDA or license records are available (total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction is supported only by a single, thematically unrelated case series (L5, model-prediction-only evidence), and the evidence pack’s own mechanistic assessment identifies this drug-disease pairing as likely a false-positive knowledge-graph association rather than a biologically plausible repurposing candidate.

To proceed, the following is needed:

Resolve blocking data gap DG001 (TFDA/FDA label warnings and contraindications) before any safety evaluation can begin
Resolve DG002 (confirmed mechanism of action documentation) to properly assess mechanistic plausibility
Disease-specific preclinical or clinical evidence directly linking phenobarbital to trigeminal nerve neoplasm, if this candidate is to be pursued further
Consider re-scoping evaluation toward higher-evidence candidates in this pack (e.g., audiogenic seizures, L3/S2) that align with phenobarbital’s known antiepileptic mechanism, rather than this L5 oncology candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.